Maureen A. McMahon, MD, MS, looks forward to a wide range of presentations on systemic lupus erythematosus, highlighting new therapies, clinical trial data, and updates on established treatments, including CAR T-cell therapies and biologics, at the upcoming American College of Rheumatology (ACR) Convergence 2025 in Chicago. Attendees will gain insight into emerging drugs, including enpatoran and new formulations such as subcutaneous anifrolumab, as well as comparative safety data for medications such as belimumab.
Practical sessions will focus on the latest ACR guidelines and their application to various lupus manifestations, including nephritis and serositis and in pediatric patients. There will also be discussions on the use of biomarkers for lupus nephritis, insights from the study of obinutuzumab in lupus nephritis, and the potential integration of medications such as GLP‑1 receptor agonists and SGLT2 inhibitors into lupus care.
